EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Effects of sodium‐glucose co‐transporter‐2 inhibitors by background cardiovascular medications: A systematic review and meta‐analysis

Ioannis Avgerinos iD, Thomas Karagiannis iD, David R Matthews iD, Apostolos Tsapas iD, Eleni Bekiari iD

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15200 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Ioannis Avgerinos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Hyperkalemia, Heart Failure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To explore whether the beneficial cardiovascular (CV) effect of sodium‐glucose co‐transporter‐2 (SGLT‐2) inhibitors is consistent with or without concurrent use of CV medications in patients with type 2 diabetes, heart failure (HF) or chronic kidney disease.

Methods

We searched Medline and Embase up to September 2022 for CV outcomes trials. The primary endpoint was the composite of cardiovascular (CV) death or hospitalization for HF. Secondary outcomes included the individual components of CV death, hospitalization for HF, death from any cause, major adverse CV events or renal events, volume depletion and hyperkalaemia. We pooled hazard ratios (HRs) and risk ratios alongside 95% confidence intervals (CIs).

Results

We included 12 trials comprising 83 804 patients. SGLT‐2 inhibitors reduced the risk of CV death or hospitalization for HF regardless of background use of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs), angiotensin receptor‐neprilysin inhibitors (ARNIs), b‐blockers, diuretics, mineralocorticoid receptor antagonists (MRAs), or triple combination therapy of either an ACEI/ARB plus b‐blocker plus MRA, or an ARNI plus b‐blocker plus MRA (HRs ranged from 0.61 to 0.83; P > .1 for each subgroup interaction). Similarly, no subgroup differences were evident for most analyses for the secondary outcomes of CV death, hospitalization for HF, all‐cause mortality, major adverse CV or renal events, hyperkalaemia and volume depletion rate.

Conclusions

The benefit of SGLT‐2 inhibitors seems to be additive to background use of CV medications in a broad population of patients. These findings should be interpreted as hypothesis generating because most of the subgroups analysed were not prespecified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2HyperkalemiaHeart FailureSymportersCardiovascular DiseasesHumansAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsGlucoseSodium

Stichwörter der Autor:innen

SGLT-2 inhibitorscardiovascular diseaseheart failuremeta-analysis

Substanzen

Angiotensin-Converting Enzyme InhibitorsSodium-Glucose Transporter 2 InhibitorsAngiotensin Receptor AntagonistsSymportersGlucoseSodium

Autor:innen und Institutionen

  • Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Diabetes Centre, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK.
  • Harris Manchester College, University of Oxford, Oxford, UK.

ORCID-Profile: Ioannis Avgerinos, Thomas Karagiannis, David R Matthews, Apostolos Tsapas, Eleni Bekiari

Zitieren

APA

Avgerinos, I., Karagiannis, T., Matthews, D. R., Tsapas, A., & Bekiari, E. (2023). Effects of sodium‐glucose co‐transporter‐2 inhibitors by background cardiovascular medications: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15200

Vancouver

Avgerinos I, Karagiannis T, Matthews DR, Tsapas A, Bekiari E. Effects of sodium‐glucose co‐transporter‐2 inhibitors by background cardiovascular medications: A systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15200

BibTeX
@article{Avgerinos2023,
  author = {Avgerinos, Ioannis and Karagiannis, Thomas and Matthews, David R and Tsapas, Apostolos and Bekiari, Eleni},
  title = {Effects of sodium‐glucose co‐transporter‐2 inhibitors by background cardiovascular medications: A systematic review and meta‐analysis},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15200}
}
Kostenlos starten →